NCT06269432CompletedPhase 4
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 1224 (actual)
- First submitted
- 29 Jan 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- Sichuan Provincial People's Hospital
- Diseases
- Stroke
- NCT number
- NCT06269432
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 1224
- From 1 Jan 2023 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications or intolerance to antiplatelet therapy medications.
Other illness
- History of recurrent stroke.
- History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders.
- Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure).
Other
- Poor compliance, inability to cooperate with study requirements.
Who the study is looking for
- Aged from 18 to 80 years;
- Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.;
- First stroke onset ≥ 1 month and ≤ 3 months;
- mRS Score \<=2 points;
- Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days;
- Informed consent signed by the patient or their family member.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sichuan Provincial People's Hospital Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.